MedPath

Morales Mantilla Gissela Paulina

🇪🇨Ecuador
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:2

Trial Phases

3 Phases

Phase 1:1
Phase 2:1
Phase 3:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 3
2 (50.0%)
Phase 1
1 (25.0%)
Phase 2
1 (25.0%)

Extended Management and Measurement of Autism

Phase 3
Terminated
Conditions
Autistic Disorder
Interventions
First Posted Date
2008-11-07
Last Posted Date
2010-02-23
Lead Sponsor
Neuropharm
Target Recruit Count
128
Registration Number
NCT00787111
Locations
🇺🇸

Southwest Autism Research and Resource Centre, Phoenix, Arizona, United States

🇺🇸

University of California Davis, Sacramento, California, United States

🇺🇸

Institute for Behavioral Medicine, Smyrna, Georgia, United States

and more 10 locations

Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome

Phase 1
Completed
Conditions
Fragile X Syndrome
First Posted Date
2008-03-17
Last Posted Date
2012-04-27
Lead Sponsor
Neuropharm
Target Recruit Count
12
Registration Number
NCT00637221
Locations
🇺🇸

MIND Institute, Sacramento, California, United States

🇺🇸

Rush University Medical Centre, Chicago, Illinois, United States

Study of Fluoxetine in Autism

Phase 3
Completed
Conditions
Autistic Disorder
Interventions
Drug: Placebo
First Posted Date
2007-08-13
Last Posted Date
2012-04-27
Lead Sponsor
Neuropharm
Target Recruit Count
158
Registration Number
NCT00515320
Locations
🇺🇸

Southwest Autism Research and Resource Centre, Phoenix, Arizona, United States

🇺🇸

University of California Davis, Sacramento, California, United States

🇺🇸

University of Florida, Department of Psychiatry, Gainesville, Florida, United States

and more 14 locations

Study of NPL-2003 in Adolescents With Obsessive Compulsive Disorder (OCD)

Phase 2
Terminated
Conditions
Obsessive Compulsive Disorder
First Posted Date
2007-08-13
Last Posted Date
2012-04-27
Lead Sponsor
Neuropharm
Target Recruit Count
6
Registration Number
NCT00515255
Locations
🇺🇸

New York State Psychiatric Institute, Columbia University, New York, New York, United States

🇺🇸

University Hospitals Case Medical Center, Cleveland, Ohio, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.